<DOC>
	<DOCNO>NCT02099461</DOCNO>
	<brief_summary>To evaluate whether administration denosumab result decrease compare control group proliferation mammary epithelial cell measure Ki-67 proliferation index .</brief_summary>
	<brief_title>Effect Denosumab Cellular Biomarkers Human Breast</brief_title>
	<detailed_description />
	<mesh_term>Denosumab</mesh_term>
	<criteria>INCLUSION CRITERIA : Willing use , combination partner , 2 nonhormonal method effective contraception practice sexual abstinence . Subjects surgically sterile ( eg , history hysterectomy ) whose sexual partner sterile ( eg , history vasectomy ) require use contraceptive measure Laboratory test within clinically acceptable range Clinically acceptable physical exam history evidence clinically significant medical disorder would pose risk subject safety interfere study evaluation procedure . EXCLUSION CRITERIA : Female subject prior history breast cancer ; breast implant breast biopsied ; Known history fibrocystic breast disease Subject unable unwilling provide breast biopsy tissue upper outer quadrant breast Pregnant plan become pregnant exposed investigational product Lactating/breastfeeding plan breastfeed expose investigational product Recent use nonapproved medication device Uncontrolled thyroid disorder Significant dental/oral disease Planned invasive dental procedure Positive urine screen alcohol and/or drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>